Navigating new frontiers: Ways to find space in the future RA market.
The auto-immune market is expected to undergo significant changes in the next few years as newer entrants with novel modes of action compete with established brands, and biosimilars become increasingly accepted for use as cheaper alternatives to the branded biologics. Increased prevalence and public awareness of auto-immune diseases is fuelling global growth.
AI is of interest to healthcare providers because of the size of the market, cost of treatment and chronic nature of many of the diseases. The NIH estimates up to 23.5 million Americans have an auto-immune disease, more than heart disease (which affects 22 million) and cancer (which affects up to 9 million people).
We have considerable experience of conducting custom market research programmes across auto-immune in rheumatoid arthritis, inflammatory bowel disease, psoriasis, psoriatic arthritis and ankylosing spondylitis amongst others.
We can help you with:
Opportunity and demand assessment
Understanding the global and local market opportunity
The patient journey and unmet needs
Segmenting the market
Product and portfolio development
Brand positioning, launch and beyond
Our custom research is complemented by global market intelligence delivered by our real-time market tracking tool, Therapy Watch. Our panels of physicians submit patient record data on autoimmune diseases every month, giving subscribers global access to the very latest market data. We are considered the gold standard in AI market monitoring.
Our Living With patient research studies provide a deeper understanding of the patient journey for people living with a chronic disease. These large, quantitative studies have been carried out across a range of therapy areas including rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis.